Replimune Group (NASDAQ:REPL) Stock Falls 4.8% Following Insider Selling

Replimune Group, Inc. (NASDAQ:REPL) fell 4.8% during mid-day trading on Wednesday after an insider sold shares in the company. The company traded as low as $22.22 and last traded at $22.1740. Approximately 1,743,679 shares were traded during trading, a decline of 60% from the average session volume of 4,312,275 shares. The stock had previously closed at $23.28.

Specifically, Director Joseph P. Slattery sold 5,200 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $21.80, for a total transaction of $113,360.00. Following the completion of the sale, the director owned 1,467 shares in the company, valued at $31,980.60. The trade was a 78.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Leerink Partners increased their price target on shares of Replimune Group from $19.00 to $31.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. JPMorgan Chase & Co. raised their price objective on shares of Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, August 26th. Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price for the company in a report on Friday, August 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Replimune Group in a research report on Monday, October 5th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.33.

Replimune Group Price Performance

The company has a current ratio of 7.11, a quick ratio of 6.90 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $2.10 billion, a PE ratio of -7.94 and a beta of 0.93. The company has a fifty day moving average price of $14.39 and a two-hundred day moving average price of $9.82.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.24. Sell-side analysts forecast that Replimune Group, Inc. will post -2.40 earnings per share for the current year.

Hedge Funds Weigh In On Replimune Group

Hedge funds have recently modified their holdings of the business. Quantinno Capital Management LP increased its stake in Replimune Group by 782.7% in the first quarter. Quantinno Capital Management LP now owns 108,477 shares of the company’s stock valued at $830,000 after purchasing an additional 96,188 shares during the period. Montanova Capital LLC boosted its stake in shares of Replimune Group by 4.0% during the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock worth $48,595,000 after buying an additional 168,000 shares during the period. Seven Fleet Capital Management LP acquired a new stake in shares of Replimune Group during the first quarter worth about $921,000. Squarepoint Ops LLC acquired a new stake in shares of Replimune Group during the second quarter worth about $1,454,000. Finally, Deutsche Bank AG purchased a new position in shares of Replimune Group during the second quarter worth about $857,000. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.